Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Orchard Therapeutics Plc ADR (ORTX)

Orchard Therapeutics Plc ADR (ORTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 744,644
  • Shares Outstanding, K 123,695
  • Annual Sales, $ 2,600 K
  • Annual Income, $ -151,980 K
  • 60-Month Beta 1.23
  • Price/Sales 302.21
  • Price/Cash Flow N/A
  • Price/Book 3.56
Trade ORTX with:

Options Overview

Details
  • Implied Volatility 84.42%
  • Historical Volatility 50.65%
  • IV Percentile 5%
  • IV Rank 2.08%
  • IV High 494.78% on 07/30/20
  • IV Low 75.70% on 03/26/21
  • Put/Call Vol Ratio 0.14
  • Today's Volume 65
  • Volume Avg (30-Day) 200
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 11,187
  • Open Int (30-Day) 7,494

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.33
  • Number of Estimates 5
  • High Estimate -0.31
  • Low Estimate -0.34
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +35.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.01 +0.17%
on 04/16/21
8.58 -29.84%
on 03/22/21
-2.02 (-25.12%)
since 03/16/21
3-Month
5.50 +9.45%
on 01/27/21
9.08 -33.70%
on 02/12/21
-1.06 (-14.97%)
since 01/15/21
52-Week
3.76 +60.11%
on 11/02/20
12.38 -51.36%
on 04/29/20
-5.07 (-45.72%)
since 04/16/20

Most Recent Stories

More News
Thinking about buying stock in Orchard Therapeutics, Salarius Pharmaceuticals, Seelos Therapeutics, Evolus, or ENDRA Life Sciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORTX, SLRX, SEEL, EOLS, and NDRA.

EOLS : 10.97 (-2.66%)
ORTX : 6.02 (-5.05%)
SEEL : 5.26 (-0.38%)
SLRX : 1.1500 (-3.36%)
NDRA : 2.18 (-1.80%)
First Week of November 19th Options Trading For Orchard Therapeutics (ORTX)

Investors in Orchard Therapeutics plc saw new options become available this week, for the November 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...

ORTX : 6.02 (-5.05%)
Health Logic Interactive Inc. Announces the Appointment of Dr. Marta New, MBA to the Advisory Board

Health Logic Interactive Inc. Announces the Appointment of Dr. Marta New, MBA to the Advisory Board

ORTX : 6.02 (-5.05%)
Thinking about buying stock in OpGen, XpresSpa, Jaguar Health, Orchard Therapeutics, or Novan?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPGN, XSPA, JAGX, ORTX, and NOVN.

NOVN : 1.1000 (-7.56%)
ORTX : 6.02 (-5.05%)
XSPA : 1.3600 (+0.74%)
JAGX : 1.3000 (-7.80%)
OPGN : 2.28 (-1.72%)
Be The Match BioTherapies(R) Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy(TM)

Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their multi-year partnership with Orchard...

ORTX : 6.02 (-5.05%)
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments

$150M Strategic Financing Supports Execution into the First Half of 2023

ORTX : 6.02 (-5.05%)
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the following virtual investor conferences:

ORTX : 6.02 (-5.05%)
What's in Store for Orchard Therapeutics (ORTX) Q4 Earnings?

Orchard Therapeutics (ORTX) will provide updates on earnings, revenues of Strimvelis and the pipeline when it releases results for fourth-quarter 2020.

AVIR : 44.94 (-2.33%)
ORTX : 6.02 (-5.05%)
IMVT : 15.42 (-2.90%)
CSTL : 65.51 (-3.90%)
Thinking about buying stock in Novan, Baudax Bio, Tyme Technologies, Orchard Therapeutics, or electroCore?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, BXRX, TYME, ORTX, and ECOR.

BXRX : 1.0700 (+0.94%)
ECOR : 1.7900 (+1.70%)
NOVN : 1.1000 (-7.56%)
ORTX : 6.02 (-5.05%)
TYME : 1.5300 (+0.66%)
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)

All eight patients treated with OTL-203 show stable cognitive function, motor function and growth within the normal range at multiple data points post-treatment

ORTX : 6.02 (-5.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based...

See More

Key Turning Points

3rd Resistance Point 6.55
2nd Resistance Point 6.44
1st Resistance Point 6.23
Last Price 6.02
1st Support Level 5.91
2nd Support Level 5.80
3rd Support Level 5.59

See More

52-Week High 12.38
Fibonacci 61.8% 9.09
Fibonacci 50% 8.07
Fibonacci 38.2% 7.05
Last Price 6.02
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar